4D Molecular Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
FDMT Nasdaq 8731 https://4dmoleculartherapeutics.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for 4D Molecular Therapeutics Inc

Here’s Why 4D Molecular Therapeutics (FDMT) Stock Boosted in Q4 - Mar 22nd, 2023 12:09 pm
4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Lags Revenue Estimates - Mar 15th, 2023 9:45 pm
4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights - Mar 15th, 2023 8:05 pm
4D Molecular Therapeutics (NASDAQ:FDMT) shareholders have earned a 38% return over the last year - Mar 2nd, 2023 10:41 am
4D Molecular Discloses Updated Data From Currently Paused Fabry Disease Cardiomyopathy Study - Feb 23rd, 2023 4:33 pm
4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium™ - Feb 22nd, 2023 9:05 pm
4DMT to Present Interim Clinical Data from INGLAXA Phase 1/2 Trials of 4D-310 for Fabry Disease Cardiomyopathy at 19th Annual WORLDSymposium™ - Feb 16th, 2023 9:05 pm
4D Molecular Therapeutics to Participate in the SVB Securities Global Biopharma Conference - Feb 8th, 2023 9:05 pm
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema - Feb 2nd, 2023 9:05 pm
BMO Capital Markets Says 4D Molecular Could Be 'Attractive Acquisition Target' - Jan 30th, 2023 5:54 pm
4D Molecular Therapeutics Announces Updates on Clinical Pipeline and Additional Preclinical Programs - Jan 9th, 2023 2:00 pm
2 ‘Strong Buy’ Stocks Goldman Sachs Predicts Will Surge at Least 40% - Dec 2nd, 2022 1:26 am
4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2022 Conference - Nov 21st, 2022 9:05 pm
2 Biotech Stocks That Can Rocket Higher in 2023, According to Wall Street - Nov 20th, 2022 10:39 am
4D Molecular (FDMT) Stock Up 178% in One Month: Here's Why - Nov 17th, 2022 3:36 pm
4D Molecular Therapeutics Shares Jump After Early Data From Wet Age-Related Macular Degeneration Trial - Nov 14th, 2022 7:07 pm
4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD) - Nov 14th, 2022 12:30 pm
4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150 for Wet AMD to be Released Monday, November 14, 2022 - Nov 10th, 2022 9:05 pm
4D Molecular Therapeutics Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag - Nov 10th, 2022 10:08 am
4D Molecular Therapeutics Reports Third Quarter 2022 Financial Results - Nov 9th, 2022 9:05 pm